BOSTON, July 8 — Vertex Pharmaceuticals announced Wednesday that it has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, marking the largest acquisition in Vertex’s history as the biotechnology giant expands beyond its leadership in cystic fibrosis into treatments for rare endocrine diseases. The transaction was announced jointly by both companies and is expected to close during the third quarter of 2026, subject to shareholder and regulatory approvals.

Under the agreement, Vertex will pay $85.00 per share in cash for Crinetics, valuing the San Diego-based biotechnology company at approximately $10 billion, or about $8.8 billion net of Crinetics’ cash on hand. The offer represents a premium of more than 100% over Crinetics’ recent closing price, sending the company’s shares sharply higher as investors welcomed the acquisition.

The purchase significantly broadens Vertex’s pipeline beyond its dominant cystic fibrosis franchise, which has generated billions of dollars in annual revenue but has also increased investor pressure on the company to diversify future growth. The acquisition immediately gives Vertex access to a newly approved commercial product while adding several late-stage drug candidates targeting rare hormonal disorders.

Among the biggest attractions is PALSONIFY, Crinetics’ once-daily oral treatment for adults with acromegaly, a rare disorder caused by excessive growth hormone production. The therapy received approval from the U.S. Food and Drug Administration in 2025 and has also secured regulatory approval in Europe.

Vertex also gains control of atumelnant, an experimental therapy currently in late-stage clinical development for congenital adrenal hyperplasia, with additional potential applications for Cushing’s syndrome. Company executives described the treatment’s clinical results as among the most promising they have seen, believing it could become a major long-term growth driver.

Executives estimate the combined commercial opportunity for the newly acquired portfolio could eventually exceed $5 billion in annual revenue, strengthening Vertex’s position as one of the biotechnology industry’s fastest-growing large-cap companies.

To finance the acquisition, Vertex will use a combination of existing cash and new debt, supported by $4.5 billion in committed bridge financing arranged by Bank of America and Morgan Stanley. Morgan Stanley and Lazard served as financial advisers to Vertex, while Kirkland & Ellis acted as legal counsel.

The acquisition continues an active year for pharmaceutical mergers as large drugmakers seek to replenish future product pipelines ahead of looming patent expirations on blockbuster medicines. Industry leaders have increasingly turned to acquisitions rather than internal development to accelerate growth, particularly in specialty and rare-disease markets where pricing power and long-term demand remain strong.

For patients, the transaction could accelerate global access to innovative therapies as Vertex brings its worldwide commercial infrastructure and financial resources to Crinetics’ growing portfolio. For investors, the deal signals that major biotechnology companies remain willing to pay substantial premiums for high-quality late-stage assets despite broader market volatility and geopolitical uncertainty.

The agreement also reinforces confidence across the biotechnology sector, demonstrating that strategic acquisitions remain a priority even as rising interest rates, inflation concerns and global market turbulence continue to weigh on corporate dealmaking. If approved, the acquisition will become one of the largest healthcare transactions completed this year and a defining milestone in Vertex’s continued evolution into a broader rare-disease powerhouse.

JBizNews Desk | Boston

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.